{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T13:10:02Z","timestamp":1756386602817,"version":"3.44.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023280","name":"CSL Seqirus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The cell culture-based inactivated influenza vaccine (ccIIV) was first approved for use in children aged 4-17\u00a0years in 2016 in the United States. The approved age indication for ccIIV was expanded to include children 6\u00a0months and older beginning the 2022-2023 season. There is limited real-world data on ccIIV effectiveness in children. We assessed ccIIV effectiveness using the test-negative design during the 2023-2024 season.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients aged 6\u00a0months to 64\u00a0years who sought outpatient or telehealth care for acute respiratory illness were actively recruited between October 2023 and May 2024. Symptom eligibility criteria included cough, with an illness duration of \u2264 7\u00a0days. Respiratory samples were tested by reverse transcription polymerase chain reaction to identify influenza cases. Vaccination dates and products were determined by immunization records. Analyses were restricted to ccIIV recipients and unvaccinated participants. Cell culture-based inactivated influenza vaccine effectiveness was estimated as [100% \u00d7 (1 \u2212 odds ratio)] for vaccination in cases versus test-negative controls, with adjustment for age and calendar time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 1850 participants, 12% were age 6\u00a0months to 3\u00a0years, 32% were age 4-17\u00a0years, and 56% were age 18-64\u00a0years. Influenza was detected in 505 (27%) participants; 267 had influenza A\/H1N1pdm09; 149 had influenza B; 56 had influenza A\/H3N2; and 33 had influenza A with unknown subtype. A total of 470 (25%) received ccIIV. Among children (age 6\u00a0months to 17\u00a0years), ccIIV effectiveness was 64% [95% confidence interval (CI), 37%-81%] against influenza A\/H1N1pdm09, 75% (95% CI, 43%-91%) against influenza B, and 76% (95% CI, 4%-97%) against influenza A\/H3N2. Among adults (age 18-64\u00a0years), ccIIV effectiveness was 56% (95% CI, 31%-73%) against influenza A\/H1N1pdm09, 62% (95% CI, 13%-86%) against influenza B, and 33% (95% CI, \u221262% to 76%) against influenza A\/H3N2. Young children aged 6\u00a0months to 3\u00a0years had the highest point estimates (88%-98%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Cell culture-based inactivated influenza vaccine generated substantial real-world effectiveness against medically attended, laboratory-confirmed influenza in children and adults during a season when influenza A\/H1N1pdm09 viruses predominated and influenza B and influenza A\/H3N2 co-circulated at lower levels.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpids\/piaf069","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T11:49:55Z","timestamp":1753876195000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2725-6439","authenticated-orcid":false,"given":"Huong Q","family":"Nguyen","sequence":"first","affiliation":[{"name":"Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute , Marshfield, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0363-6229","authenticated-orcid":false,"given":"Oluwakemi D","family":"Alonge","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute , Marshfield, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5117-8279","authenticated-orcid":false,"given":"Kayla E","family":"Hanson","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute , Marshfield, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisha","family":"Stefanski","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute , Marshfield, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5696-965X","authenticated-orcid":false,"given":"Joshua G","family":"Petrie","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute , Marshfield, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karita","family":"Ambrose","sequence":"additional","affiliation":[{"name":"Medical Affairs, CSL Seqirus , Summit, NJ ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashesh","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Medical Affairs, CSL Seqirus , Summit, NJ ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Bissonnette","sequence":"additional","affiliation":[{"name":"Integrated Research and Development Laboratory , Marshfield Clinic Research Institute, Marshfield, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C","family":"Sylvester","sequence":"additional","affiliation":[{"name":"Medical Affairs, CSL Seqirus , Summit, NJ ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer K","family":"Meece","sequence":"additional","affiliation":[{"name":"Integrated Research and Development Laboratory , Marshfield Clinic Research Institute, Marshfield, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7478-0415","authenticated-orcid":false,"given":"Edward A","family":"Belongia","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute , Marshfield, WI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"2025082808314009100_ref1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1111\/irv.12486","article-title":"Annual estimates of the burden of seasonal influenza in the United States: a tool for strengthening influenza surveillance and preparedness","volume":"12","author":"Rolfes","year":"2018","journal-title":"Influenza Other Respir Viruses"},{"key":"2025082808314009100_ref2","doi-asserted-by":"publisher","first-page":"e665","DOI":"10.1093\/cid\/ciaa371","article-title":"Relative effectiveness of the cell-cultured quadrivalent influenza vaccine compared to standard, egg-derived quadrivalent influenza vaccines in preventing influenza-like illness in 2017-2018","volume":"71","author":"Boikos","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025082808314009100_ref3","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1016\/j.vaccine.2019.06.004","article-title":"Comparing influenza vaccine effectiveness between cell-derived and egg-derived vaccines, 2017-2018 influenza season","volume":"37","author":"DeMarcus","year":"2019","journal-title":"Vaccine"},{"key":"2025082808314009100_ref4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1093\/infdis\/jiy716","article-title":"Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017-2018","volume":"220","author":"Izurieta","year":"2019","journal-title":"J Infect Dis"},{"key":"2025082808314009100_ref5","doi-asserted-by":"publisher","first-page":"ofae175","DOI":"10.1093\/ofid\/ofae175","article-title":"Relative vaccine effectiveness of cell- vs egg-based quadrivalent influenza vaccine against test-confirmed influenza over 3 seasons between 2017 and 2020 in the United States","volume":"11","author":"Stein","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2025082808314009100_ref6","doi-asserted-by":"publisher","first-page":"e692","DOI":"10.1093\/cid\/ciaa1944","article-title":"Relative effectiveness of the cell-derived inactivated quadrivalent influenza vaccine versus egg-derived inactivated quadrivalent influenza vaccines in preventing influenza-related medical encounters during the 2018-2019 influenza season in the United States","volume":"73","author":"Boikos","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025082808314009100_ref7","doi-asserted-by":"publisher","first-page":"ofac532","DOI":"10.1093\/ofid\/ofac532","article-title":"Relative effectiveness of cell-based versus egg-based quadrivalent influenza vaccines in adults during the 2019-2020 influenza season in the United States","volume":"9","author":"Imran","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2025082808314009100_ref8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/INF.0000000000003620","article-title":"Relative effectiveness of cell-based versus egg-based quadrivalent influenza vaccines in children and adolescents in the United States during the 2019-2020 influenza season","volume":"41","author":"Imran","year":"2022","journal-title":"Pediatr Infect Dis J"},{"volume-title":"Flucelvax","year":"2024","key":"2025082808314009100_ref9"},{"volume-title":"Flucelvax Quadrivalent","year":"2024","key":"2025082808314009100_ref10"},{"key":"2025082808314009100_ref11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7101a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2022-23 influenza season","volume":"71","author":"Grohskopf","year":"2022","journal-title":"MMWR Recomm Rep"},{"volume-title":"TaqPath\u2122 COVID-19, FluA, FluB Combo Kit Instructions for Use","year":"2022","author":"Thermofisher Scientific","key":"2025082808314009100_ref12"},{"key":"2025082808314009100_ref13","doi-asserted-by":"publisher","first-page":"10309","DOI":"10.1128\/JVI.01109-09","article-title":"Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and swine origin human influenza a viruses","volume":"83","author":"Zhou","year":"2009","journal-title":"J Virol"},{"key":"2025082808314009100_ref14","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1186\/s12864-016-3030-6","article-title":"Viral deep sequencing needs an adaptive approach: IRMA, the iterative refinement meta-assembler","volume":"17","author":"Shepard","year":"2016","journal-title":"BMC Genomics"},{"key":"2025082808314009100_ref15","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.21105\/joss.03773","article-title":"Nextclade: clade assignment, mutation calling and quality control for viral genomes","volume":"6","author":"Aksamentov","year":"2021","journal-title":"J Open Source Softw"},{"key":"2025082808314009100_ref16","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7202a1","article-title":"Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices\u2014United States, 2023\u201324 influenza season","volume":"72","author":"Grohskopf","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"2025082808314009100_ref17","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.vaccine.2013.02.053","article-title":"The test-negative design for estimating influenza vaccine effectiveness","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"2025082808314009100_ref18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/ije\/dym021","article-title":"Methodologic issues regarding the use of three observational study designs to assess influenza vaccine effectiveness","volume":"36","author":"Orenstein","year":"2007","journal-title":"Int J Epidemiol"},{"key":"2025082808314009100_ref19","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1016\/j.vaccine.2013.04.026","article-title":"The case test-negative design for studies of the effectiveness of influenza vaccine","volume":"31","author":"Foppa","year":"2013","journal-title":"Vaccine"},{"key":"2025082808314009100_ref20","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES2013.18.37.20585","article-title":"The test-negative design: validity, accuracy and precision of vaccine efficacy estimates compared to the gold standard of randomised placebo-controlled clinical trials","volume":"18","author":"De Serres","year":"2013","journal-title":"Euro Surveill"},{"key":"2025082808314009100_ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.12763","article-title":"Evaluating the test-negative design for COVID-19 vaccine effectiveness using randomized trial data: a secondary cross-protocol analysis of 5 randomized clinical trials","volume":"8","author":"Andrews","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2025082808314009100_ref22","doi-asserted-by":"publisher","first-page":"8047","DOI":"10.1016\/j.vaccine.2018.10.093","article-title":"Influenza vaccine effectiveness among patients with high-risk medical conditions in the United States, 2012-2016","volume":"36","author":"Shang","year":"2018","journal-title":"Vaccine"},{"key":"2025082808314009100_ref23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1056\/NEJMoa1700153","article-title":"Influenza vaccine effectiveness in the United States during the 2015-2016 season","volume":"377","author":"Jackson","year":"2017","journal-title":"N Engl J Med"},{"key":"2025082808314009100_ref24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025082808314009100_ref25","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae658","article-title":"Influenza vaccine effectiveness against medically attended outpatient illness, United States, 2023-24 season","author":"Chung","year":"2025","journal-title":"Clin Infect Dis"},{"key":"2025082808314009100_ref26","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70023","article-title":"Influenza vaccine effectiveness against symptomatic influenza in primary care: a test negative case control study over two influenza seasons 2022\/2023 and 2023\/2024 in Ireland","volume":"18","author":"Marron","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"2025082808314009100_ref27","doi-asserted-by":"publisher","first-page":"2400089","DOI":"10.2807\/1560-7917.ES.2024.29.8.2400089","article-title":"Interim 2023\/24 influenza a vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024","volume":"29","author":"Maurel","year":"2024","journal-title":"Euro Surveill"},{"key":"2025082808314009100_ref28","doi-asserted-by":"publisher","first-page":"2400076","DOI":"10.2807\/1560-7917.ES.2024.29.7.2400076","article-title":"2023\/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)","volume":"29","author":"Skowronski","year":"2024","journal-title":"Euro Surveill"},{"key":"2025082808314009100_ref29","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2024.29.2.2300709","article-title":"Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023\/24 season","volume":"29","author":"Smolarchuk","year":"2024","journal-title":"Euro Surveill"},{"key":"2025082808314009100_ref30","doi-asserted-by":"publisher","DOI":"10.1111\/irv.13284","article-title":"Interim 2023\/2024 season influenza vaccine effectiveness in primary and secondary care in the United Kingdom","volume":"18","author":"Whitaker","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"key":"2025082808314009100_ref31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229279","article-title":"Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season","volume":"15","author":"Klein","year":"2020","journal-title":"PLoS One"},{"key":"2025082808314009100_ref32","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/cid\/ciz075","article-title":"Effects of influenza vaccination in the United States during the 2017-2018 influenza season","volume":"69","author":"Rolfes","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2025082808314009100_ref33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025082808314009100_ref34","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1056\/NEJMoa2024848","article-title":"Efficacy of a cell-culture-derived quadrivalent influenza vaccine in children","volume":"385","author":"Nolan","year":"2021","journal-title":"N Engl J Med"},{"key":"2025082808314009100_ref35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3390\/vaccines9020080","article-title":"Clinical and economic outcomes associated with cell-based quadrivalent influenza vaccine vs. standard-dose egg-based quadrivalent influenza vaccines during the 2018-19 influenza season in the United States","volume":"9","author":"Krishnarajah","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"2025082808314009100_ref36","doi-asserted-by":"publisher","first-page":"6334","DOI":"10.1016\/j.vaccine.2020.07.023","article-title":"A real-world study evaluating the relative vaccine effectiveness of a cell-based quadrivalent influenza vaccine compared to egg-based quadrivalent influenza vaccine in the US during the 2017-18 influenza season","volume":"38","author":"Divino","year":"2020","journal-title":"Vaccine"},{"key":"2025082808314009100_ref37","doi-asserted-by":"publisher","first-page":"e146138","DOI":"10.1172\/JCI146138","article-title":"Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination","volume":"131","author":"Liu","year":"2021","journal-title":"J Clin Invest"},{"key":"2025082808314009100_ref38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bsheal.2019.02.007","article-title":"Mutations associated with egg adaptation of influenza A(H1N1)pdm09 virus in laboratory based surveillance in China, 2009\u20132016","volume":"1","author":"Yang","year":"2019","journal-title":"Biosaf Health"},{"volume-title":"2023-2024 Influenza Season Summary: Influenza Severity Assessment, Burden and Burden Prevented","year":"2024","author":"Centers for Disease Control and Prevention","key":"2025082808314009100_ref39"},{"key":"2025082808314009100_ref40","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.15585\/mmwr.mm7241a2","article-title":"High influenza incidence and disease severity among children and adolescents aged &lt;18 years\u2014United States, 2022-23 season","volume":"72","author":"White","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"volume-title":"Past Flu Season Severity Assessments","year":"2024","author":"Centers for Disease Control and Prevention","key":"2025082808314009100_ref41"},{"volume-title":"Pediatric Flu Deaths Reach 200 for the 2023-24 Flu Season","year":"2024","author":"Centers for Disease Control and Prevention","key":"2025082808314009100_ref42"},{"volume-title":"Flu Vaccination Coverage, United States, 2023\u201324 Influenza Season","year":"2024","author":"Centers for Disease Control and Prevention","key":"2025082808314009100_ref43"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piaf069\/63891466\/piaf069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/8\/piaf069\/63891466\/piaf069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/14\/8\/piaf069\/63891466\/piaf069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:31:50Z","timestamp":1756384310000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/doi\/10.1093\/jpids\/piaf069\/8219023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piaf069","relation":{},"ISSN":["2048-7207"],"issn-type":[{"type":"electronic","value":"2048-7207"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,7,30]]},"article-number":"piaf069"}}